Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.53
+0.07000.45%
Post-market: 15.52-0.0100-0.06%19:30 EDT
Volume:567.53K
Turnover:8.84M
Market Cap:999.43M
PE:-4.48
High:15.95
Open:15.41
Low:15.24
Close:15.46
52wk High:23.19
52wk Low:6.50
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.11
PE(LYR):-4.17

Loading ...

Small U.S. Stocks Close Lower; Cullinan Therapeutics Posts Biggest Loss

Dow Jones
·
Sep 24

Cullinan Therapeutics Down over 20%, on Track for Record Percent Decrease

Dow Jones
·
Sep 24

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

GlobeNewswire
·
Sep 22

Cullinan Management (CGEM) Gets a Buy from Wedbush

TIPRANKS
·
Sep 15

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), High Tide (HITI) and Cullinan Management (CGEM)

TIPRANKS
·
Sep 15

Cullinan Maintained at Buy on Zipalertinib Strength, Unchanged $33 Price Target

TIPRANKS
·
Sep 15

Cullinan Therapeutics Price Target Raised to $40.00/Share from $39.00 by BTIG

Dow Jones
·
Sep 15

Cullinan Therapeutics price target raised to $40 from $39 at BTIG

TIPRANKS
·
Sep 15

Cullinan Highlights Positive Phase 3 Lung Cancer Results

TIPRANKS
·
Sep 14

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

GlobeNewswire
·
Sep 14

Cullinan, Taiho Say Zipalertinib Plus Chemo Lifts Median PFS by 6 Months in Phase 3 Rezilient3 Trial

Reuters
·
Sep 14

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in Rezilient3 Phase 3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 14

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

GlobeNewswire
·
Sep 11

Cullinan Therapeutics CSO Jennifer Michaelson Disposes 8,000 Common Shares Worth $172,560

Reuters
·
Sep 10

Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next

Simply Wall St.
·
Aug 22

Cullinan, Taiho say results of Phase 3 trial selected for presentation

TIPRANKS
·
Aug 20

Cullinan Says Rezilient3 Interim Data for Zipalertinib Plus Chemotherapy in EGFR Exon 20 NSCLC Lands IASLC WCLC 2026 Presidential Symposium Slot

Reuters
·
Aug 20

UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating

MT Newswires Live
·
Aug 17

Morgan Stanley Keeps Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
Aug 17

Cullinan Therapeutics Price Target Maintained with a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 17